What is the global market size of Dry Eye Disease Market?

Dry Eye Disease Market size was valued at USD 5.13 billion in 2021 and is poised to grow from USD 5.53 billion in 2022 to USD 10.92 billion by 2030, growing at a CAGR of 7.85% in the forecast period (2023-2030).

Global Dry Eye Disease Market Size, Share, Growth Analysis, By Product(Artificial Tears, Anti-inflammatory Drugs), By Distribution Channel(Hospital Pharmacies, Independent Pharmacies & Drug Stores) - Industry Forecast 2024-2031

Report ID: SQMIG35D2172 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 65 | Figures: 75

Global Dry Eye Disease Market Insights

Dry Eye Disease Market size was valued at USD 5.13 billion in 2019 and is poised to grow from USD 5.53 billion in 2023 to USD 10.92 billion by 2031, growing at a CAGR of 7.85% in the forecast period (2024-2031).

Dry eye is an ocular surface disease that causes the eye to produce insufficient tears and is associated with symptoms of ocular discomfort. Keratitis sicca, keratoconjunctivitis sicca (KCS), xerophthalmia, dry eye syndrome (DES), and dysfunctional tear syndrome are all names for dry eye disease (DTS). Clinical trials and research and development activities are expected to gain traction in order to increase the penetration of dry eye treatments and medications.

Dry eye disease affects a significant proportion of the global population (from middle to old age). Women are more likely than men to contract the disease. According to the World Health Organization Facts of 2021, the proportion of the global population aged 60 and up will nearly double between 2015 and 2050, rising from 12% to 22%. By 2050, low- and middle-income countries will house 80% of the world's elderly. The elderly population is expected to grow, and this group is more vulnerable to eye-related disorders such as dry eye. This factor could influence the market in the future.

US Dry Eye Disease Market is poised to grow at a sustainable CAGR for the next forecast year.

Global Dry Eye Disease Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

The market for dry eye disease is moderately competitive. In terms of market share, the market is currently dominated by a few major players. With the growing geriatric population and high disease prevalence, a few new smaller players are expected to enter the market in the coming years. AbbVie Inc. (Allergan PLC), Alcon Inc., and Santen Pharmaceutical Co. are among the market's major players. 'Allergan plc (now part of AbbVie Inc.)', 'Novartis AG', 'Santen Pharmaceutical Co., Ltd.', 'Johnson & Johnson', 'Otsuka Pharmaceutical Co., Ltd.', 'Shire (now part of Takeda Pharmaceutical Company Limited)', 'Sun Pharmaceutical Industries Ltd.', 'Bausch Health Companies Inc.', 'Alcon Inc. (a subsidiary of Novartis AG)', 'AbbVie Inc.', 'Akorn, Inc.', 'Nicox SA', 'Mitotech S.A.', 'Tarsus Pharmaceuticals, Inc.', 'Kala Pharmaceuticals, Inc.', 'Novaliq GmbH', 'Oyster Point Pharma, Inc.', 'AFT Pharmaceuticals Ltd.', 'OcuSoft, Inc.', 'Eyenovia, Inc.'

Dry eye disease, also known as keratoconjunctivitis sicca (KCS), is a common ophthalmic disorder that affects about 360 million people worldwide. Patients complain of dryness, irritation, redness, fatigue, and blurred vision. The prevalence varies with age, but it is increasing in both the young and old populations due to increased screen time, poor diet, increased use of contact lenses, and an increase in the number of LASIK surgeries. The ability of the lachrymal glands to produce tears decreases with age, resulting in dry eyes. One of the key factors contributing to the growth of the global dry eye drugs market is the rising incidence of dry eye disease due to an ageing population.

One of the leading market trends in the dry eye disease market has been an increase in R&D spending, successful clinical trials, and increased new product approvals. A large number of companies are involved in clinical trials, such as Aldeyra Therapeutics, Inc.'s pipeline candidate Reproxalap, which is currently in Phase - III. This type of initiative is expected to drive the dry eye disease treatment market's revenue generation.

The global dry eye disease market is studied on the basis of geography as North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Due to the high prevalence of dry eye diseases and the ease with which solutions are available in the region, North America is expected to hold a significant share of the dry eye disease market. In this multi-screen world, people of all ages can be found. Computer or digital screen use may result in less blinking, which may contribute to symptoms of dry eye disease (DED), thereby increasing the demand for better and more effective DED therapeutics, which is expected to fuel growth in the North American region studied.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Global Dry Eye Disease Market Size, Share, Growth Analysis, By Product(Artificial Tears, Anti-inflammatory Drugs), By Distribution Channel(Hospital Pharmacies, Independent Pharmacies & Drug Stores) - Industry Forecast 2024-2031

Global Dry Eye Disease Market Insights

Global Dry Eye Disease Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Dry Eye Disease Market?

Who are the key vendors in the Global Dry Eye Disease Market?

What is the key driver of Global Dry Eye Disease Market?

What is the key market trend for Global Dry Eye Disease Market?

Which region accounted for the largest share in Global Dry Eye Disease Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300